Electric Literature of 13627-49-1, In the chemical reaction process,reaction time,type of solvent,can easily affect the result of the reaction, thereby determining the yield and properties of the reaction product.An updated downstream synthesis route of 13627-49-1 as follows.
A mixture of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (227 mg, 1 .0 mmol), 2-methylpyrimidine-4-carboxylic acid (138 mg, 1 .0 mmol), 2-(7-azabenzotriazol-1 -yl)-A/,A/,A/’,A/’-tetramethyluronium hexafluorophosphate (570 mg, 1 .5 mmol) and diisopropylethylamine (390 mg, 3.0 mmol) in A/,A/-dimethylformamide (4 ml_) was stirred at room temperature for 1 h. The mixture was poured into water. The formed precipitate was collected by filtration and the obtained solid was washed with methanol (15 ml_) to afford A/-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (0.228 g, 0.66 mmol, 66%) as a grey solid. 1 H NMR (500 MHz, Dimethylsulfoxide-c/6) d 10.40 (s, 1 H), 9.05 (d, J = 5.0 Hz, 1 H), 8.40 (d, J – 2.0 Hz, 1 H), 8.19 (d, J = 8.5 Hz, 1 H), 7.96 (d, J = 5.5 Hz, 1 H), 7.84 (dd, J = 8.5, 2.5 Hz, 1 H), 7.72-7.70 (m, 2H), 7.60 (d, J = 5.5 Hz, 1 H), 4.06 (s, 2H), 2.78 (s, 3H); LCMS (ESI) m/z: 348.1 [M+H]+.
These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route,13627-49-1, its application will become more common.
Reference:
Patent; YUMANITY THERAPEUTICS, INC.; LE BOURDONNEC, Bertrand; LUCAS, Matthew; OZBOYA, Kerem; PANDYA, Bhaumik; TARDIFF, Daniel; TIVITMAHAISOON, Parcharee; WRONA, Iwona; (475 pag.)WO2019/183587; (2019); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia